Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

NCT02724579 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT02724579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02724579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 17, 2017
Completion date
March 31, 2028
Enrollment
45 (estimated)
Sites
195

Conditions

As the registry lists them; a condition with its own page is linked.

medulloblastoma